John G. Ullman & Associates’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-67,819
Closed -$1.27M 173
2022
Q1
$1.27M Sell
67,819
-113,513
-63% -$2.04M 0.18% 91
2021
Q4
$3.88M Buy
181,332
+58,813
+48% +$1.16M 0.53% 50
2021
Q3
$2.26M Buy
+122,519
New +$2.47M 0.31% 67

Other funds holding OCDX

John G. Ullman & Associates's OCDX Position: Q2 2022 in Review

John G. Ullman & Associates sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 67,819 shares — an estimated $1.27M sold.

John G. Ullman & Associates first reported a position in OCDX in Q3 2021 and held it in 3 quarters. The position peaked at $3.88M in Q4 2021. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

  • John G. Ullman & Associates reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • John G. Ullman & Associates sold 67,819 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $1.27M.
  • John G. Ullman & Associates first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q3 2021 and held it in 3 quarters.
  • John G. Ullman & Associates's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $3.88M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on John G. Ullman & Associates's 13F filing for Q2 2022, filed 27 Jul 2022.